<DOC>
	<DOC>NCT01006603</DOC>
	<brief_summary>This study will evaluate the efficacy and tolerability of saxagliptin compared to glimepiride in elderly patients with type 2 diabetes mellitus who have inadequate glycaemic control on metformin monotherapy.</brief_summary>
	<brief_title>Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Established clinical diagnosis of type 2 diabetes. Treatment with a stable metformin monotherapy, for at least 8 weeks prior to Visit 1 HbA1c ≥7.0% and ≤9.0% Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar nonketonic coma. Current use of any injectable or oral antihyperglycemic agent excluding metformin. Renal impairment as defined by a creatinine clearance &lt;60 mL/min Individuals who, in the opinion of the investigator, in which participation in this study may pose a significant risk to the patient and could render the patient unable to successfully complete the study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>elderly patients</keyword>
	<keyword>saxagliptin</keyword>
	<keyword>randomised</keyword>
	<keyword>double-blind</keyword>
</DOC>